

Final Report for the Year Ended 30 June 2024
RESULTS FOR ANNOUNCEMENT TO THE MARKET

The following information is presented in accordance with ASX listing rule 4.3A and should be read in conjunction with the attached EBOS Group Limited Financial Report for the year ended 30 June 2024.

1. DETAILS OF THE REPORTING PERIOD AND THE PREVIOUS CORRESPONDING PERIOD

Current period: The year ended 30 June 2024
 Previous corresponding period: The year ended 30 June 2023

This report and the attached Consolidated Financial Report are presented in Australian dollars, being the Group's presentation currency.

2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

Group Results (Audited)	30 June 2024 AUD \$000	30 June 2023 AUD \$000	Change %
Revenue	13,189,054	12,237,401	7.8%
Earnings before depreciation, amortisation, net finance costs and tax expense (EBITDA)	605,595	568,776	6.5%
Depreciation and amortisation	(128,871)	(124,784)	(3.3%)
Earnings before interest and tax (EBIT)	476,724	443,992	7.4%
Profit before tax (PBT)	383,103	373,431	2.6%
Net profit after tax (NPAT)	273,085	263,445	3.7%
Net profit after tax (NPAT) attributable to owners of the Company	271,549	253,373	7.2%
Weighted average number of shares	192,168	190,602	0.8%
Basic EPS – (CPS)	141.3	132.9	6.3%
Net tangible asset backing per ordinary share – (\$)	(\$4.18)	(\$3.53)	
Underlying EBITDA (refer reconciliation below)	624,343	582,010	7.3%
Underlying EBIT (refer reconciliation below)	521,653	484,165	7.7%
Underlying PBT (refer reconciliation below)	428,032	413,604	3.5%
Underlying Net profit after tax (NPAT) attributable to the owners of the Company (refer reconciliation below)	303,405	281,828	7.7%
Underlying EPS – (CPS)	157.9	147.9	6.8%

Dividends	Amount Per Share (NZ\$ Cents)	Franked amount per security to 30% tax rate
Final dividend payable 18 September 2024	61.5c	100%
Final dividend – previous corresponding period	57.0c	100%
Key dates for the 2024 Final Dividend		
Ex-dividend date		29 August 2024
Record date		30 August 2024 (5.00pm NZST)
Dividend payment date		18 September 2024
Other Comments		
The final dividend will be imputed to 25% for New Zealand tax resident shareholders and a supplementary dividend paid to eligible non-resident shareholders.		

3. RECONCILIATION OF REPORTED TO UNDERLYING EARNINGS

Reconciliation of Reported to Underlying Earnings (Audited)	30 June 2024 AUD \$000	30 June 2023 AUD \$000	Change %
Reported EBITDA	605,595	568,776	6.5%
Add back underlying earnings adjustments in the period ¹	18,748	13,234	
Underlying EBITDA	624,343	582,010	7.3%
Reported EBIT	476,724	443,992	7.4%
Add back underlying earnings adjustments in the period ¹	44,929	40,173	
Underlying EBIT	521,653	484,165	7.7%
Reported PBT	383,103	373,431	2.6%
Add back underlying earnings adjustments in the period ¹	44,929	40,173	
Underlying PBT	428,032	413,604	3.5%
Reported Net Profit after Tax (NPAT) attributable to owners of the Company	271,549	253,373	7.2%
Add back underlying earnings adjustments in the period ¹ (net of tax and after non-controlling interests)	31,856	28,455	
Underlying Net Profit after Tax (NPAT) attributable to owners of the Company	303,405	281,828	7.7%

¹ Underlying EBITDA, Underlying EBIT, Underlying PBT and Underlying Net Profit after Tax attributable to the owners of the Company are non-GAAP measures. Refer to Appendix 1 for details.

For supplementary comments on the Group's financial results refer to the Results Presentation and Results Media Release issued 21 August 2024.

4. CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Please refer to the Consolidated Statement of Comprehensive Income in the attached Consolidated Financial Report for the year ended 30 June 2024.

5. CONSOLIDATED BALANCE SHEET

Please refer to the Consolidated Balance Sheet in the attached Consolidated Financial Report for the year ended 30 June 2024.

6. CONSOLIDATED CASH FLOW STATEMENT

Please refer to the Consolidated Cash Flow Statement in the attached Consolidated Financial Report for the year ended 30 June 2024.

7. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Please refer to the Consolidated Statement of Changes in Equity in the attached Consolidated Financial Report for the year ended 30 June 2024.

8. DIVIDENDS PAID AND DECLARED

Group Results (Audited)	Amount Per Share (NZ\$ Cents)	Amount Per Share (A\$ Cents)	Total Amount (A\$)	Date Paid / Payable
Dividends declared in respect of the year ended 30 June 2024				
2024 final dividend	61.5 cents	56.8 cents	\$109,788,000	18 September 2024
Dividends paid during the year ended 30 June 2024				
2023 final dividend	57.0 cents	52.7 cents	\$100,879,000	29 September 2023
2024 interim dividend	57.0 cents	53.7 cents	\$102,796,000	22 March 2024
	114.0 cents	106.4 cents	\$203,675,000	
Dividends paid during the year ended 30 June 2023				
2022 final dividend	49.0 cents	43.9 cents	\$83,001,000	30 September 2022
2023 interim dividend	53.0 cents	48.2 cents	\$92,610,000	17 March 2023
	102.0 cents	92.1 cents	\$175,611,000	

Dividends are approved by the Board in New Zealand dollars. Dividends recognised in the Statement of Changes in Equity are converted from New Zealand dollars to Australian dollars at the exchange rate applicable on the date the dividend was approved. Unrecognised dividends are converted at the exchange rate applicable on the reporting date.

9. DIVIDEND REINVESTMENT PLAN

The Company's dividend reinvestment plan ('DRP') will be operable for this dividend. The EBOS Board has approved a discount of 2.5% to the Volume Weighted Average Sales Price ('VWAP') for the shares to be issued under the DRP for the 2024 final dividend.

10. ENTITIES ACQUIRED

Refer to Note B2 of the attached Consolidated Financial Report for the Financial Year ended 30 June 2024.

11. ASSOCIATES AND JOINT VENTURES

The Group equity accounted the following associate entities at 30 June 2024.

Name of business	Proportion of shares and voting rights
Animates NZ Holdings Limited	50.00%
Good Price Pharmacy Franchising Pty Limited	44.18%
Good Price Pharmacy Management Pty Limited	44.18%

Income from the individual Associates has not been separately disclosed as it is considered immaterial. Total income from Investments in Associates for the year ended 30 June 2024 was \$12,938,000 (2023: \$12,369,000).

12. OTHER SIGNIFICANT INFORMATION

Refer to the attached Consolidated Financial Report for the year ended 30 June 2024.

13. FOREIGN ENTITIES

The Consolidated Financial Statements are presented in Australian dollars and comply with International Financial Reporting Standards ("IFRS").

14. COMMENTARY ON THE RESULTS FOR THE PERIOD

14.1 The earnings per security and the nature of any dilution.

Please refer to Note A4 of the attached Consolidated Financial Report for the year ended 30 June 2024.

14.2 Returns to shareholders including distributions and buy backs.

Please refer to Notes E1 and E2 of the attached Consolidated Financial Report for the year ended 30 June 2024.

14.3 Significant features of operating performance.

Please refer to the attached Consolidated Financial Report for the year ended 30 June 2024 and to the Results Media Release and Results Presentation issued on 21 August 2024.

14.4 The results of segments that are significant to an understanding of the business as a whole.

Please refer to Note A2 of the attached Consolidated Financial Report for the year ended 30 June 2024.

14.5 A discussion of trends in performance.

Please refer to the attached Consolidated Financial Report for the year ended 30 June 2024 and to the Results Media Release and Results Presentation issued on 21 August 2024.

14.6 Any other factors which have affected the results in the period or which are likely to affect results in the future, including those where the effect could not be quantified.

Please refer to the Results Media Release and Results Presentation issued on 21 August 2024.

15. INDEPENDENT AUDIT OPINION

The Consolidated Financial Statements included in the Consolidated Financial Report have been audited by an independent auditor, and the auditor has given an unmodified opinion.

16. AUDIT COMMITTEE

The entity has a formally constituted Audit and Risk Committee.

ANNUAL MEETING

The annual meeting will be held as follows:

Place:

Park Hyatt Auckland, 99 Halsey Street,
Auckland, New Zealand

Date:

Wednesday, 23 October 2024

Time:

2:00pm

Approximate date the annual
report will be available:

Wednesday, 21 August 2024
(via website: www.ebosgroup.com)

APPENDIX 1

Note 1: Underlying EBITDA, Underling EBIT, Underling PBT and Underlying Net Profit after Tax attributable to the owners of the Company are non-GAAP measures.

Underlying earnings for the 30 June 2024 period exclude one-off M&A costs (\$10.1m pre tax, \$7.5m post tax) primarily associated with a large strategic transaction which did not proceed, non-recurring restructuring costs and site transition costs (which primarily includes staff redundancies) to enable future underlying growth (\$8.6m pre tax, \$6.1m post tax) and the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets (\$26.2m pre tax, \$18.3m post tax).

Underlying earnings for the 30 June 2023 period exclude Medical Technology division integration costs (\$12.5m pre tax, \$8.9m post tax), one-off M&A costs (\$0.7m pre tax, \$0.7m post tax) and the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition PPA of finite life intangible assets (\$26.9m pre tax, \$18.9m post tax).